SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst mixed sentiment, with some community members expressing frustration over price action and lack of utility, while others remain confident and are accumulating. There's also discussion of newer meme coins potentially outperforming SHIB, and comparisons to other coins like DOGE. Some users mention a broader market downturn affecting altcoins.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express bullish sentiment and highlight the project's strong community. Many reference the "WAGMI" (We're All Gonna Make It) ethos, emphasizing belief and conviction in the project's long-term potential within the crypto space. The community is actively adding to their positions and welcomes new members.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential, particularly the strength of its meme coin economy and upcoming partnerships. Several Solana-based tokens, like $PJ and $PEPEK, are gaining traction within the Phantom Wallet ecosystem. Traders are also watching for potential breakout patterns and the possibility of a Solana ETF.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending, with community members highlighting its recent activity on Phantom Wallet. The coin is described as having strong momentum, with users encouraging others to buy in early. Some users are pointing to the coin's chart and community growth as positive signals.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

$GIGA is trending as the community rallies around the meme coin, expressing strong conviction with 'WAGMI' sentiments and 'DCA' strategies. Talk centers on its potential within the Solana meme coin ecosystem and its strong community.

Ethena

Ethena (ENA) is trending amid discussions about its potential growth and recent news, including a proposed buyback program and integration with other platforms. The community is actively debating its bullish potential, particularly its correlation with other cryptos and possible price targets. Many are drawn to Ethena's connection to stablecoins and real-world asset tokenization.

SSgA Active Trust - The Energy Select Sector SPDR Fund

Energy Select Sector SPDR Fund

XLE is trending due to geopolitical tensions, with community members discussing potential supply disruptions and rising oil prices amid conflict in the Middle East. Some traders are anticipating a short-term pop, while others believe that broader market factors will prevail. The ETF's recent performance, dividend yield, and long-term trend indicators are also being weighed by investors.

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Solana Co. - Ordinary Shares - Class A

Solana Co

HSDT is trending due to a recent announcement of a $500M funding round aimed at launching a Solana-backed treasury. The community is debating whether this move will be a game-changer or lead to dilution, with some traders eyeing potential short squeezes and comparing the stock's movements to $SOL.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community anticipates the mainnet launch and a potential Coinbase listing. Discussions revolve around its potential to connect all blockchains and banks, rivaling established cryptos like XRP and SOL. Speculation about major partnerships and its unique 'anchor' technology are also fueling the conversation.

Plume is the first RWAfi L1 network focused on crypto natives. We build infrastructure to make it easy to connect the real world and the crypto markets. We go against the traditional view of RWAs by changing its definition – it’s not just TradFi onchain but instead building net new crypto-first RWA use cases to the market including things like RWA derivatives/speculation, borrow/lend, yield farming, and more.  We are a permissionless EVM chain and ecosystem that is redefining and driving the RWA market forward. We do this through novel technologies that vertically integrate all the elements of RWAs into a single stack and ecosystem. Our tokenization engine, an EVM chain, compliance & regulatory tooling, RWA data normalization, etc are all first class objects so that they work seamlessly together to make it easy to bring anything in the real world (assets, data, etc.) onchain.

Plume Network

Plume Network is gaining attention as a Layer-1 blockchain focused on Real World Asset (RWA) tokenization, with discussions centering on its utility compared to governance tokens like ONDO. Recent news highlights include Apollo's $50M credit fund going on-chain via Plume and Centrifuge, as well as Plume's integration with Binance Pay, which has captured the interest of the community.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Prothena Down 40% Year to Date: What Lies Ahead for the Stock? 

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects to advance a drug developed by Prothena into a late-stage study for ATTR amyloidosis with cardiomyopathy.On Stocktwits, retail sentiment around Prothena jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1332/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_1_09_34_PM_png_9facc97342.webp" alt="PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1332" height="122"><figcaption>PRTA's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for Prothena stock.<stembedurl>https://stocktwits.com/stocks271/message/623950128</stembedurl>Shares of Prothena traded 13% higher at the time of writing, while NYSE-listed shares of Novo traded 4% down.ATTR amyloidosis with cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease where misfolded transthyretin (TTR) proteins deposit in the heart muscle, leading to heart failure. Prothena-developed Coramitug is designed to deplete the abnormal protein deposits.Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. During Novo’s earnings call on Wednesday, the company said that it has successfully completed a mid-stage study of the drug and will now initiate a late-stage study during the course of 2025. The company also said that it will share detailed data from the mid-stage study at a medical conference later this year.Under the terms of the agreement between Prothena and Novo Nordisk, the former company is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones.Prothena is also eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the late-stage clinical trial. To date, Prothena has earned $100 million from the deal.PRTA stock is down by 43% this year and by about 61% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Equity

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.


Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -67.57% and -79.20%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well

RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.

AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies

AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? 

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD. 

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net cash burn from operating and investing activities to between $170 million and $178 million.&nbsp;The forecast follows a sweeping corporate restructuring that includes discontinuing development of birtamimab, an investigational therapy for AL amyloidosis, expected to reduce annual cash burn by about $96 million, and laying off 63% of its workforce.The biotech expects to end 2025 with roughly $298 million in cash, cash equivalents, and restricted cash at the midpoint.The revised cash burn outlook includes an estimated net loss of $240 million to $248 million, incorporating $36 million in non-cash share-based compensation and a $45 million non-cash tax expense related to deferred tax assets.The operating cost estimate includes $105 million to $110 million tied to birtamimab and reorganization-related expenses, such as severance and contract terminations.&nbsp;The company’s board and financial advisors are reviewing strategic options as it pivots to focus on its remaining pipeline and partnered programs.&nbsp;Prothena said it is reviewing strategic options as several clinical milestones approach, including Roche’s Phase 3 plans for prasinezumab in Parkinson’s, August data from Prothena’s PRX012 Alzheimer’s trial, and 2026 milestone payments of up to $105 million from partnered programs with Novo Nordisk and Bristol Myers Squibb.On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.One user expressed confidence in Prothena’s prospects, indicating the stock may have substantial upside potential and encouraging a broader, long-term perspective on its trajectory.<stembedurl>https://stocktwits.com/alromofi777/message/618389231</stembedurl>Another user said the cost and workforce reductions were largely anticipated, adding they plan to sell if shares hold above $6 on Friday following the recent rebound from lows.<stembedurl>https://stocktwits.com/SQUEAKSBANDIT/message/618364635</stembedurl>The stock has declined 57.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast

The biotech firm expects to end 2025 with nearly $300 million in cash as it pivots to focus on its Alzheimer’s and Parkinson’s pipeline.

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena Corporation plc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PRTA
Prothena Corporation plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRTA News

PRTAProthena Corporation plc